Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
SELECTA生物科学公司和银杏生物工程公司联手开发罕见疾病治疗药物
- Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.
- The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
- Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
- Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
- Related: Selecta In-Licenses Rights To IgG Protease Platform.
- Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
- Selecta生物科学公司(纳斯达克股票代码：SELB)和银杏生物工程控股有限公司纽约证券交易所股票代码：DNA)合作设计了针对孤儿和罕见疾病的新型和改进的潜在治疗酶。
- 这一合作关系将利用银杏的细胞编程平台和Selecta的ImmTOR平台来创造潜在的变革性酶疗法。
- SELECTA已获得开发和商业化用于治疗特定自身免疫性疾病的精选治疗酶的权利。
- 根据合作条款，银杏有资格获得预付研发费用和里程碑，包括某些里程碑付款，包括Selecta普通股、临床和商业里程碑付款，最高可达8500万美元现金。
- 相关： Selecta In-License Right to IgG Protease Platform(选择IgG蛋白酶平台许可权).
- 价格行动：周二尾盘，SELB股价上涨7.24%，至3.83美元，DNA股价上涨6.09%，至15.15美元。